The WJOG9717L study, which compared osimertinib monotherapy with osimertinib plus bevacizumab in previously untreated Japanese patients harboring EGFR mutations, revealed that 18.3% of the patients experienced pneumonitis.20 Here, EGFR is linked to pneumonitis.